Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06749366 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Minor Study description revised
    • Eligibility criteria expanded, about 1 word
  2. Minor 4 versions Re-verified since Apr 27, 2026, no change to tracked fieldsv34-v37
  3. Minor Study description revisedv33
  4. Minor 10 versions Re-verified since Jan 31, 2025, no change to tracked fieldsv23-v32
  5. Minor Start date changed from estimate of Feb 3, 2025 to Jan 27, 2025v22
Show 20 earlier versionsHide 20 earlier versions
  1. Minor Start date: Feb 2, 2025 to Feb 3, 2025v21
  2. Minor Start date: Jan 30, 2025 to Feb 2, 2025v20
  3. Minor Start date: Jan 29, 2025 to Jan 30, 2025v19
  4. Minor Start date: Jan 28, 2025 to Jan 29, 2025v18
  5. Minor Start date: Jan 27, 2025 to Jan 28, 2025v17
  6. Minor Start date: Jan 22, 2025 to Jan 27, 2025v16
  7. Minor Start date: Jan 21, 2025 to Jan 22, 2025v15
  8. Minor Start date: Jan 20, 2025 to Jan 21, 2025v14
  9. Minor Start date: Jan 19, 2025 to Jan 20, 2025v13
  10. Minor Start date: Jan 16, 2025 to Jan 19, 2025v12
  11. Minor Start date: Jan 15, 2025 to Jan 16, 2025v11
  12. Minor Start date: Jan 14, 2025 to Jan 15, 2025v10
  13. Minor Start date: Jan 13, 2025 to Jan 14, 2025v9
  14. Minor Start date: Jan 12, 2025 to Jan 13, 2025v8
  15. Minor Start date: Jan 9, 2025 to Jan 12, 2025v7
  16. Minor Start date: Jan 8, 2025 to Jan 9, 2025v6
  17. Minor Start date: Jan 6, 2025 to Jan 8, 2025v5
  18. Minor Start date: Jan 5, 2025 to Jan 6, 2025v4
  19. Minor Start date: Jan 2, 2025 to Jan 5, 2025v3
  20. Minor Start date: Jan 1, 2025 to Jan 2, 2025v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Background: Ollier disease (OD) and Maffucci syndrome (MS) are rare disorders that increase the risk of cancers in cartilage tissue. These tumors can lead to severe skeletal deformities beginning in childhood. People with OD or MS are also at an increased risk of blood vessel disorders and specific cancers. Researchers want to learn more about what causes these disorders. Objective: To understand the genetic causes of OD and MS. Eligibility: People aged 2 years and older who have OD or MS with cartilage tumors or blood vessel disorders. Design: Participants will stay at the NIH clinic for 5 days. They will undergo these procedures: A physical exam with blood tests. DXA (dual-energy X-ray absorptiometry) scan. The DXA scan measures the density of bones. Participants will lie on a table while a machine uses low-level X-rays to scan their body. MRI (magnetic resonance imaging) scan. An MRI uses strong magnets to take pictures of the tissues inside the body. Participants will lie on a table that slides into a large tube. A contrast dye may be injected through a needle inserted into a vein in the arm. X-rays. Some participants may have full-body X-rays instead of an MRI. X-rays take pictures of bones and other internal tissues and organs, such as the heart, lungs, and airways. PET (positron emission tomography) and CT (computed tomography) scans. Adult participants will have 2 other scans. The PET scan will include a radioactive injection into a vein. They will also have a full-body CT scan.
Trial Details
NCT Number NCT06749366
Lead Sponsor Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Conditions
(from sponsor)
Enchondromatosis
Related terms Chondroma, Chondrosarcoma, Enchondromatosis, Hemangioma, Mucopolysaccharidosis IV
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov